The Scale of the Lab Space Boom
The U.S. life sciences real estate market experienced one of its most dramatic expansions in history between 2020 and 2025. According to a recent Savills report, nearly 60 million square feet of lab space was delivered across 11 major U.S. markets during this period. Annual deliveries surged from roughly 4.5 million square feet in 2020 to 14.5 million square feet in 2025 — more than tripling in just five years.
Two markets dominated this wave of development. Boston-Cambridge and the San Francisco Bay Area together accounted for 58 percent of all new lab supply, reinforcing how deeply concentrated the life sciences sector remains in its two legacy hubs. Together, these cities shaped the market’s trajectory more than any other factor.
The Vacancy Problem That Followed
That burst of construction has since collided with a far softer leasing environment. Savills found that 55.6 percent of newly delivered life sciences space across the U.S. remains unoccupied. Furthermore, in 2025 alone, about 10.7 million square feet of the 14.5 million square feet delivered — or 73.4 percent — was still vacant as of February 2026. These numbers are not just signs of a slowdown. They signal a sector in active reset mode.
Why Overbuilding Followed Enthusiasm
Real Demand Met with Speculative Supply
The confidence that fueled this construction boom was not entirely unfounded. During and after the pandemic, life sciences real estate looked like a rare property type backed by deep structural demand, premium rents, and long-term relevance. Investors wanted exposure to biotech, therapeutics, and research. Meanwhile, developers saw a product category that appeared insulated from the upheaval hitting traditional office markets.
Cities also played a role. Municipal leaders wanted to attract innovation tenants, while landlords sought a narrative more durable than the uncertainty surrounding workplace real estate. As a result, lab space became one of the few sectors where growth still seemed reliable and scalable.
However, Enthusiasm Outpaced Demand
The core problem, though, was that the market was not simply responding to genuine tenant demand. It was responding to enthusiasm. A sector can have real long-term promise and still be overbuilt in the near term — especially when too many projects launch on the assumption that yesterday’s leasing conditions will continue indefinitely. That assumption proved costly.
How Tenant Behavior Is Changing
Selectivity Is Replacing Speed
The tenant base is no longer behaving the way it did during the peak years. Research budgets have tightened. Growth plans have stretched out. Occupancy decisions have changed accordingly. Today, tenants take less space, delay commitments, and negotiate harder than they did just a few years ago.
Moreover, companies are now far more selective about the buildings they choose. In the boom period, the core advantage for landlords was simply having lab product available. In the current environment, the advantage has shifted entirely. Landlords now must offer product that specifically matches a more discerning tenant’s needs — not just four walls and lab-ready infrastructure.
Smaller Footprints, Longer Timelines
Additionally, early-stage companies and established biotech firms alike are reconsidering how much space they actually need. Rather than securing large, long-term commitments, many tenants prefer smaller footprints with options to expand. This behavioral shift is putting further pressure on vacancy rates in markets where large-format suites were built for a leasing environment that no longer exists.
What Landlords Must Do Differently Now
Competing on More Than Lab Readiness
Landlords can no longer compete on lab readiness alone. Tenants in today’s market evaluate economics, flexibility, and speed to occupancy alongside technical specifications. Therefore, owners who can offer adaptable suites, efficient buildouts, and structures that reduce upfront risk for occupiers are positioned to outperform those who cannot.
Three Priorities for Competitive Landlords
Flexibility in suite design is now essential. Buildings that allow for modular configurations — where tenants can right-size their footprint — will attract more interest than those locked into fixed large-block layouts.
Reduced upfront cost burden matters more than it did during the boom. Landlords offering generous tenant improvement allowances, phased rent structures, or pre-fitted suites are better positioned to close deals in this environment.
Speed to occupancy has become a differentiator. Tenants no longer want to wait 12 to 18 months for a custom buildout. Consequently, buildings with move-in-ready suites, even at a modest premium, hold a clear competitive edge.
The Road Ahead for Life Sciences Real Estate
A Painful but Necessary Reset
The current downturn may ultimately be healthy for the sector, even if it feels difficult in the short term. The market is no longer rewarding life sciences space as an abstract idea. Instead, it is rewarding actual tenant demand, genuine operating advantages, and locations with enduring research gravity.
Long-Term Fundamentals Remain Solid
Life sciences real estate still rests on strong long-term fundamentals. The tenant base is tied to industries with real scientific momentum, ongoing government research funding, and strategic importance to the broader economy. Biotech, pharmaceuticals, gene therapy, and diagnostics are not going away. Consequently, the underlying demand for quality lab space will persist.
A More Mature Asset Class Is Emerging
Nevertheless, the era when almost any lab project could be framed as a sure-fire investment is clearly over. What is taking shape now is something more mature and more recognizable: a real estate asset class with powerful long-term demand drivers, uneven short-term conditions, and significantly less room for speculative excess.
That shift may ultimately define the next phase of this market more than any individual vacancy rate. In the boom period, the advantage was simply having lab product. In this new environment, the advantage belongs to landlords with product that can match a more selective, cost-conscious, and operationally specific tenant base.
